Business Context and Reporting Period
Company: Cactus Ventures, Inc. (Note: Input metadata referenced "Actinium Pharmaceuticals," but the filing text identifies the registrant as Cactus Ventures, Inc., a Nevada corporation formerly known as Zurich U.S.A., Inc.)
Reporting Period: Fiscal year ended December 31, 2008.
Business Model: The Company is a "blank check" shell company with no active operations, employees, or specific business plan. Its sole objective is to locate and negotiate a merger or acquisition with a target business entity to provide a path to public reporting status. The Company ceased its previous sunglasses marketing operations due to vendor issues.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(31,243) | $(24,313) |
| Total Expenses | $26,419 | $21,505 |
| Interest Expense | $4,824 | $2,808 |
| Cash and Cash Equivalents | $2,218 | $2,314 |
| Total Assets | $2,218 | $2,314 |
| Total Liabilities | $76,179 | $45,032 |
| Shareholders' Deficit | $(73,961) | $(42,717) |
| Working Capital | $(24,134) | $(6,759) |
Debt Structure: Liabilities consist primarily of a $49,827 note payable to related parties (extended to Dec 31, 2009), $12,360 in accounts payable, and $5,490 in accrued legal fees. Interest rates on related party loans are 12% for pre-2008 loans and 8% for post-2008 loans.
Material Changes vs. Prior Period
- Increased Losses: Net loss increased by approximately 28% from $24,313 in 2007 to $31,243 in 2008, driven by higher professional fees and interest expenses.
- Deteriorating Liquidity: Working capital deficit widened significantly from $(6,759) to $(24,134) due to a sharp increase in current liabilities (from $9,073 to $26,352) while cash remained stagnant.
- Related Party Debt: Notes payable to related parties increased by $13,868 (from $35,959 to $49,827) to fund ongoing compliance and administrative costs.
- Stock Structure: A 1-for-2 reverse stock split was effective December 18, 2007, resulting in 11,155,008 shares outstanding as of the reporting date.
Outlook, Risks, and Management Commentary
Going Concern: The independent auditor has issued a "going concern" opinion, stating that the Company's net losses, negative working capital, and stockholders' deficit raise substantial doubt about its ability to continue operations without additional financing.
Liquidity and Capital Resources: The Company has negligible cash ($2,218) and relies entirely on advances from its President/Director to cover operating expenses. Management anticipates expenses of approximately $20,000 for the next 12 months but offers no assurance that advances will continue.
Market Status: Common stock trades on the OTCBB under symbol "CTVN." There was no active market or trading volume in 2008. The stock is subject to "Penny Stock" rules, which severely restrict liquidity and resale.
Risks:
- Acquisition Uncertainty: No target company has been identified, and there is no assurance a merger will occur.
- Dilution: Any future business combination will likely involve issuing significant shares, causing substantial dilution to current shareholders.
- Management Concentration: The Company has no employees; operations depend entirely on the sole officer/director, Diane S. Button, who devotes limited time to the business.
Investor Verification Checklist
- Identity Verification: Confirm the registrant is Cactus Ventures, Inc. (CTVN), not Actinium Pharmaceuticals, as the metadata may be mismatched.
- Related Party Dependence: Verify the status of the $49,827 debt owed to related parties and the willingness of the President to continue funding operations.
- Going Concern Status: Assess the risk of insolvency given the negative working capital of $(24,134) and lack of revenue.
- Stock Liquidity: Confirm the lack of trading volume and the impact of Penny Stock regulations on the ability to sell shares.
- Management Dilution: Note that the sole officer owns 89.65% of outstanding shares; any merger will likely drastically alter this ownership structure.